Although GLP-1 mimetics show glucose-lowering efficacies as well as notable weight-loss effects, treatment with exenatide and sitagliptin, GLP-1–derived medications, was supposed to increase cancer risk, especially pancreatic and thyroid carcinomas [3]. This evidence concerns the gene GCG and thyroid gland carcinoma.